Annals of the American Thoracic Society | 2021
The Societies’ Responsibility for Wellness: Healing for the Healer
Abstract
1 Torres A, Cilloniz C, Niederman MS, Men endez R, Chalmers JD, Wunderink RG, et al. Pneumonia. Nat Rev Dis Primers 2021;7:25. 2 Cill oniz C, Gabarr us A, Ferrer M, Puig de la Bellacasa J, Rinaudo M, Mensa J, et al. Community-acquired pneumonia due to multidrugand non-multidrug-resistant Pseudomonas aeruginosa. Chest 2016;150: 415–425. 3 SibilaO, LasernaE,Maselli DJ, Fernandez JF,MortensenEM, Anzueto A, et al. Risk factors and antibiotic therapy in P. aeruginosa communityacquired pneumonia. Respirology 2015;20:660–666. 4 Restrepo MI, Babu BL, Reyes LF, Chalmers JD, Soni NJ, Sibila O, et al.; GLIMP. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. Eur Respir J 2018;52:1701190. 5 Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am JRespir Crit CareMed 2019;200:e45–e67. 6 Sando E, Suzuki M, Ishida M, Yaegashi M, Aoshima M, Ariyoshi K, et al. Definitive and indeterminate Pseudomonas aeruginosa infection in adults with community-acquired pneumonia: a prospective observational study. Ann Am Thorac Soc 2021;18:1475–1481. 7 Aliberti S, Di Pasquale M, Zanaboni AM, Cosentini R, Brambilla AM, Seghezzi S, et al. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis 2012;54:470–478. 8 Shorr AF, Zilberberg MD, Reichley R, Kan J, Hoban A, Hoffman J, et al. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis 2012;54:193–198. 9 Webb BJ, Dascomb K, Stenehjem E, Vikram HR, Agrwal N, Sakata K, et al. Derivation and multicenter validation of the drug resistance in pneumonia clinical prediction score. Antimicrob Agents Chemother 2016;60:2652–2663. 10 FalconeM, Russo A, Giannella M, Cangemi R, Scarpellini MG, Bertazzoni G, et al. Individualizing risk of multidrug-resistant pathogens in community-onset pneumonia. PLoS One 2015;10:e0119528. 11 Prina E, Ranzani OT, Polverino E, Cill oniz C, Ferrer M, Fernandez L, et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc 2015;12: 153–160. 12 Ceccato A, Mendez R, Ewig S, de la Torre MC, Cilloniz C, Gabarrus A, et al. Validation of a prediction score for drug-resistant microorganisms in community-acquired pneumonia. Ann Am Thorac Soc 2021; 18:257–265. 13 Taniguchi T, Tsuha S, Shiiki S, Narita M. Gram-stain-based antimicrobial selection reduces cost and overuse compared with Japanese guidelines. BMC Infect Dis 2015;15:458.